Products

Products COR-101 The fully human antibody COR-101 is the lead product in our current pipeline. It binds to the viral RBD region and blocks the attachment of the virus to human cells. In pre-clinical studies, COR-101 decreased the SARS-CoV-2 virus load in the lung by...

Privacy-Statement

Privacy Statement Effective Since: August, 13th 2021   We respect the privacy of our users and treat their personal data in the strictest confidentiality and in accordance with the legislation in force. The privacy statement is intended to inform you, in a...

Cookie policy

Cookie policy Effective Since: June, 21st 2021   This policy relating to cookies (hereinafter, the »Cookie Policy«) describes the different types of cookies that we use on our website: www.corat-therapeutics.com (hereinafter, the »Website«) and the manner in...

Clinical trials

Clinical Trials Text/English Text/Deutsch Clinical Study In order to gain information about the risks and the effectiveness of our therapeutic COVID-19 antibodies, we conduct clinical trials. Currently, our lead candidate COR-101 is evaluated in an international phase...

News & Events

News & Events News / press releases Categories All Events News 2021 2020 Reset CORAT Therapeutics GmbH announces partnership with Dermapharm Holding SE Jul 7, 2021 CORAT Therapeutics GmbH announces partnership with Dermapharm Holding SE read more CORAT antibody...